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Insulin-like growth factor binding protein-2 (IGFBP-2) is
widely abundant in fetal life and remains highly
expressed in the brain throughout life. It plays a key
role in targeting IGFs to their receptors in developing
organs [1]. It is also highly expressed by a broad range
of aggressive cancers such that its ablation reduces can-
cer growth. IGFBP-2 has also recently been recognised
to play a key role in metabolic regulation.
We have been investigating the role and mechanisms of
action of IGFBP-2, and have developed unique insights into
its structure-function relationships. Our work has mostly
focused on neuroblastoma cell lines of varying aggressive-
ness and motility, and our manipulations of the IGFBP-2
molecule have allowed functional characterisation.
We have demonstrated that the IGFBP-2 molecule
contains a critical central basic region, the heparin-bind-
ing domain (HBD), which accounts for its binding to
cell surface, critical in targeting IGFs to their receptors.
Ablation of this domain dramatically reduces both pro-
liferation and motility of these cancer cells, a process
also involving integrin receptors [2].
This same region of the molecule also contains a
Nuclear Localisation Sequence (NLS) accounting for the
ability of IGFBP-2 to enter the cell nucleus. This process
leads to induction of transcription of a range of cancer-
promoting genes including VEGF, promoting angiogenesis
in a chick embryo model, intrinsic to carcinogenesis. Abla-
tion of the NLS blocks these processes [2,3].
Circulating IGFBP-2 is reduced in obesity and other
insulin-resistant states and in animal models can enhance
insulin sensitivity. It is regulated by the insulin sensitiser,
leptin, and in a sheep model we have demonstrated that
centrally administered leptin induces IGFBP-2 expression
in skeletal muscle, via the sympathetic nervous system.
Similarly, leptin applied directly to cultured skeletal muscle
cells induces IGFBP-2 expression, leading to enhanced
insulin sensitivity. This suggests that IGFBP-2 may mediate
leptin’s insulin-sensitising effects [4].
IGFBP-2 also acts on visceral, but not subcutaneous adi-
pose tissue, inhibiting fat accumulation, an effect not seen
when the HBD region is mutated or integrin blockade is
applied. Thus IGFBP-2 appears to play a beneficial role in
regulating the function of visceral fat, which is critical in
the pathogenesis of metabolic complications of obesity.
IGFBP-2 is thus a critical player in both cancer biology
and in metabolic syndrome. There is potential for targeted
pharmacologic manipulation of IGFBP-2 activity in order
to reduce the morbidity and mortality of these major
diseases in our society.
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